Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism

Obesity Surgery

Volumn 27, Issue 3, 2017, Pages 569-577

  Vilarrasa, Nuria ^a,b   de Gordejuela, Amador García Ruiz ^a   Casajoana, Anna ^a   Duran, Xevi ^c   Toro, Silvia ^a   Espinet, Eduard ^a   Galvao, Manoel ^d   Vendrell, Joan ^b,c   López Urdiales, Rafael ^a   Pérez, Manuel ^a,b   Pujol, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d Gastro Obeso Center   (Brazil)

Author keywords

Duodenal jejunal bypass liner; Endobarrier; Gastrointestinal hormones; Ghrelin; Glucagon; Glucagon like; Grade I obese patients; Peptide 1; Peptide YY; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEPTIDE YY; SULFONYLUREA; TRIACYLGLYCEROL; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE SAFETY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIGESTIVE SURGICAL EQUIPMENT; DISEASE DURATION; DUODENAL JEJUNAL BYPASS LINER; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN TREATMENT; MALE; MEAL; METABOLIC REGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THERAPY EFFECT; BARIATRIC SURGERY; BLOOD; CLINICAL TRIAL; COMPLICATION; DEVICE REMOVAL; DEVICES; GASTROINTESTINAL ENDOSCOPY; GLUCOSE BLOOD LEVEL; METABOLISM; MORBID OBESITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSTHESIS IMPLANTATION;

ADULT; BARIATRIC SURGERY; BLOOD GLUCOSE; DEVICE REMOVAL; DIABETES MELLITUS, TYPE 2; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY, MORBID; PROSTHESIS IMPLANTATION;

EID: 84979971333     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-016-2311-0     Document Type: Article

References (32)

1. Kumar N. Endoscopic therapy for weight loss: gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastrointest Endosc. 2015;7(9):847–59.
2. Gersin KS, Keller JE, Stefanidis D, Simms CS, Abraham DD, Deal SE, et al. Duodenal jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14:275–8.
3. Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4:55–9.
4. Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, et al. Open label, prospective, randomized controlled trials of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for preoperative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–6.
5. Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.
6. Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080–5.
7. De Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvão Neto MP, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.
8. Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.
9. Muñoz R, Dominguez A, Muñoz F, Muñoz C, Slako M, Turiel D, et al. Baseline glycated hemoglobin levels are associated with duodenal jejunal bypass liner-induced weight loss in obese patients. Surg Endosc. 2014;28(4):1056–62.
10. de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal–jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354–60.
11. Cohen R, le Roux CW, Papamargaritis D, Vincent RP, Bloom SR, Buurman WA, et al. Role of proximal gut exclusion from food on glucose homeostasis in patients with type 2 diabetes. Diabet Med. 2013;30(12):1482–6.
12. De Jonge C, Rensen S, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, et al. Impact of duodenal-jejunal exclusion on satiety hormones. Obes Surg. 2016;26:672–8.
13. American Diabetes Association. Standards of Medical care in Diabetes 2015. Diabetes Care. 2015; 38(suppl 1).
14. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab. 2002;4:19–28.
15. de Moura EG, Lopes GS, Martins BC, Orso IR, Coutinho AM, de Oliveira SL, et al. Effects of duodenal-jejunal bypass liner (EndoBarrier®) on gastric emptying in obese and type 2 diabetic patients. Obes Surg. 2015;25(9):1618–25.
16. Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005; 589–598.
17. Hickey MS, Pories WJ, Macdonald KG, Cory KA, Dohm GL, Swanson MS, et al. A new paradigm for type 2 diabetes mellitus. Could it be a disease of the foregut? Ann Surg. 1998;227:637–44.
18. Dirken C, Jorgensen NB, Bojsen-Moller KN, Jacobsen SH, Hansen DL, Worm D, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55:1890–901.
19. Näslund E, Grybäck P, Hellström PM, Jacobsson H, Holst JJ, Theodorsson E, et al. Gastrointestinal hormones and gastric emptying 20 years after jejuno ileal bypass for massive obesity. Int J Obes Relat Metab Disord. 1997;21:387–92.
20. Horowitz M, Cook DJ, Collins PJ, Harding PE, Hooper MJ, Walsh JF, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655–7.
21. Marathe C, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36(5):1396–405.
22. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. Clin Endocrinol Metab. 2001;86(8):3853–60.
23. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–13.
24. le Roux CW, Aylwin SJ, Batterham RL. Gut hormone profiles following bariatric surgery favor an anoretic state, facilitate weight loss and improve metabolic parameters. Ann Surg. 2006;243:108–14.
25. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992.
26. Cummings D, Weigle D, Frayo S, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.
27. Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol. 2002;56:203–6.
28. Quesada I, Tuduri E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol. 2008;199:5–19.
29. D-Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011;13(Suppl 1):126–32.
30. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011;13(11):965–71.
31. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513–48.
32. Betzel B, Koehestanie P, Aarts EO, Dogan K, Homan J, Janssen IM, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc. 2015;82:845–52.